Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. Co. is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the U.S. Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. We show 64 historical shares outstanding datapoints in our coverage of NBIX's shares outstanding history.
Understanding the changing numbers of NBIX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NBIX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NBIX by allowing them to research NBIX shares outstanding history
as well as any other stock in our coverage universe. |
Free NBIX Email Alerts:
Video: Shares Outstanding Importance
